Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data

• Ida Kappel Buhl ,

  Contributed equally to this work with: Ida Kappel Buhl, Sarah Gerster

  Affiliations Section for Molecular Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Medical Prognosis Institute, Hoersholm, Denmark

  ⨯
• Sarah Gerster ,

  Contributed equally to this work with: Ida Kappel Buhl, Sarah Gerster

  Current address: Swiss National Science Foundation, Bern, Switzerland

  Affiliation Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland

  ⨯
• Mauro Delorenzi,

  Affiliations Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland, Ludwig Center for Cancer Research and Oncology Department, University of Lausanne, Lausanne, Switzerland

  ⨯
• Thomas Jensen,

  Affiliation Medical Prognosis Institute, Hoersholm, Denmark

  ⨯
• Peter Buhl Jensen,

  Affiliation Medical Prognosis Institute, Hoersholm, Denmark

  ⨯
• Fred Bosman,

  Affiliation University of Lausanne, University Institute of Pathology, Lausanne, Switzerland

  ⨯
• Sabine Tejpar,

  Affiliation University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, Belgium

  ⨯
• Arnaud Roth,

  Affiliation University Hospital of Geneva, Oncosurgery Unit, Geneva, Switzerland

  ⨯
• Nils Brunner,

  Affiliation Section for Molecular Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

  ⨯
• Anker Hansen,

  Affiliation Medical Prognosis Institute, Hoersholm, Denmark

  ⨯
• Steen Knudsen

  * E-mail: steen@medical-prognosis.com

  Affiliation Medical Prognosis Institute, Hoersholm, Denmark

  ⨯